Table 1.
List of selected glioblastoma clinical trials using drugs targeted against enzymes involved in epigenetic modifications.
| Drug | Role | Clinical trial number | Clinical trial phase | Selected references |
|---|---|---|---|---|
| Vorinostat | HDAC inhibitor |
NCT00762255 NCT01266031 NCT01110876 NCT03426891 NCT01342757 NCT00555399 NCT00731731 NCT00641706 NCT00238303 NCT00939991 NCT01738646 NCT01189266 NCT00268385 NCT01378481 |
I (completed) I (completed) I (terminated) I (recruiting) N/A I/II I/II II (completed) II (completed) I/II II (completed) I/II I I (terminated) |
(101–107) |
| Romidepsin | HDAC inhibitor | NCT00085540 | I/II (completed) | (108) |
| Belinostat | HDAC inhibitor | NCT02137759 | II | (109) |
| Panobinostat (LBH589) | HDAC inhibitor |
NCT01115036 NCT00848523 |
II (withdrawn) II (terminated) |
(110) |
| Valproic acid | HDAC inhibitor |
NCT02648633 NCT02758366 NCT01817751 NCT01861990 NCT03243461 NCT00302159 |
I (terminated) II II I (withdrawn) III II (completed) |
(111–117) |
| Olaparib | PARP inhibitor |
NCT02974621 NCT01390571 NCT03212274 |
II I (completed) II (recruiting) |
(118, 119) |
| Veliparib (ABT-888) | PARP inhibitor |
NCT02152982 NCT00770471 NCT01026493 NCT03581292 NCT01514201 |
II/III I (completed) I/II (completed) II (recruiting) I/II (completed) |
(120, 121) |
| Iniparib (BSI-201) | PARP inhibitor | NCT00687765 | I (completed) | (122) |
| CBL0137 | Histone chaperone FACT inhibitor | NCT01905228 | I (recruiting) | (123–125) |
HDAC, histone deacetylase; PARP, poly(ADP-ribose) polymerase; FACT, facilitates chromatin transcription; N/A, not applicable.